INS and type 1 diabetes mellitus: In this post hoc analysis of data from the inTandem3 trial of sotagliflozin as an adjunct to insulin in patients with T1D, median BHB levels increased by 0.04 mmol/L from a baseline of 0.13 mmol/L after 24 weeks of treatment with sotagliflozin versus placebo.